The DOI matches its Crossref record; 42 of the 44 references it cites were found in a registry or an index.
Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid
Abstract
The preclinical pharmacology of the alpha4beta2 nicotinic acetylcholine receptor (nAChR) partial agonist varenicline, a novel smoking cessation agent is described. Varenicline binds with subnanomolar affinity only to alpha4beta2 nAChRs and in vitro functional patch clamp studies in HEK cells expressing nAChRs show that varenicline is a partial agonist with 45% of nicotine's maximal efficacy at alpha4beta2 nAChRs. In neurochemical models varenicline has significantly lower (40-60%) efficacy than nicotine in stimulating [(3)H]-dopamine release from rat brain slices in vitro and in increasing dopamine release from rat nucleus accumbens in vivo, while it is more potent than nicotine. In addition, when combined with nicotine, varenicline effectively attenuates the nicotine-induced dopamine release to the level of the effect of varenicline alone, consistent with partial agonism. Finally, varenicline reduces nicotine self-administration in rats and supports lower self-administration break points than nicotine. These data suggest that varenicline can reproduce to some extent the subjective effects of smoking by partially activating alpha4beta2 nAChRs, while preventing full activation of these receptors by nicotine. Based on these findings, varenicline was advanced into clinical development and recently shown to be an effective and safe aid for smoking cessation treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“neither patch (Jorenby et al., 1995) nor varenicline are reinforcing (Rollema et al., 2007).”
From It is not “either/or”: Activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and mood (2008) · cites this paper as Rollema et al., 2007
In the citing paper
“Varenicline, the most effective medication for smoking cessation currently available (Chantix; Pfizer), is a potent partial agonist for a4b2 nAChRs, as well as a weak partial agonist at a3b4 nAChRs and a full agonist at a7 nAChRs (Coe et al, 2005; Rollema et al, 2007).”
From Divergent Functional Effects of Sazetidine-A and Varenicline During Nicotine Withdrawal (2013) · cites this paper as Rollema et al, 2007
In the citing paper
“Varenicline, the most effective medication for smoking cessation currently available (Chantix; Pfizer), is a potent partial agonist for a4b2 nAChRs, as well as a weak partial agonist at a3b4 nAChRs and a full agonist at a7 nAChRs (Coe et al, 2005; Rollema et al, 2007).”
From Divergent Functional Effects of Sazetidine-A and Varenicline During Nicotine Withdrawal (2013) · cites this paper as Rollema et al, 2007
In the citing paper
“Varenicline, the most effective medication for smoking cessation currently available (Chantix; Pfizer), is a potent partial agonist for a4b2 nAChRs, as well as a weak partial agonist at a3b4 nAChRs and a full agonist at a7 nAChRs (Coe et al, 2005; Rollema et al, 2007).”
From Divergent Functional Effects of Sazetidine-A and Varenicline During Nicotine Withdrawal (2013) · cites this paper as Rollema et al, 2007
In the citing paper
“Varenicline (Chantix; Pfizer, Groton, CT) is a potent partial agonist at ␣42 nAChRs, with 40 to 60% of the agonist efficacy of nicotine (Rollema et al., 2007), and it is a less potent partial agonist at ␣34 and a full agonist at ␣7 nAChRs (Mihalak et al., 2006;Rollema et al., 2007Rollema et al., , 2009b)).”
From Nicotinic Partial Agonists Varenicline and Sazetidine-A Have Differential Effects on Affective Behavior (2010) · cites this paper as Rollema et al., 2007
In the citing paper
“Varenicline (Chantix; Pfizer, Groton, CT) is a potent partial agonist at ␣42 nAChRs, with 40 to 60% of the agonist efficacy of nicotine (Rollema et al., 2007), and it is a less potent partial agonist at ␣34 and a full agonist at ␣7 nAChRs (Mihalak et al., 2006;Rollema et al., 2007Rollema et al., , 2009b)).”
From Nicotinic Partial Agonists Varenicline and Sazetidine-A Have Differential Effects on Affective Behavior (2010) · cites this paper as Rollema et al., 2007
In the citing paper
“Although the K i values for sazetidine-A and varenicline at ␣42 nAChRs are very similar (0.4 and 0.2 nM, respectively) (Xiao et al., 2006;Rollema et al., 2007)”
From Nicotinic Partial Agonists Varenicline and Sazetidine-A Have Differential Effects on Affective Behavior (2010) · cites this paper as Rollema et al., 2007
In the citing paper
“the high-affinity ␣42 partial agonist varenicline also has moderate affinity for other nAChRs and acts as a partial agonist at ␣34 and a full agonist at ␣7 nAChRs (Mihalak et al., 2006;Rollema et al., 2007).”
From Nicotinic Partial Agonists Varenicline and Sazetidine-A Have Differential Effects on Affective Behavior (2010) · cites this paper as Rollema et al., 2007
In the citing paper
“Although varenicline, like cytisine, is a potent and selective ␣42 partial agonist (Rollema et al., 2007)”
From Nicotinic Partial Agonists Varenicline and Sazetidine-A Have Differential Effects on Affective Behavior (2010) · cites this paper as Rollema et al., 2007
In the citing paper
“Varenicline has at least 100-fold higher affinity for α4β2 than for other subtypes, is a 45% agonist as compared with nicotine and can potently desensitize α4β2 nicotinic acetylcholine receptors with an IC50 value of 6 nM for inhibiting nicotine-evoked currents (Rollema et al., 2007).”
From Varenicline has antidepressant-like activity in the forced swim test and augments sertraline's effect (2009) · cites this paper as Rollema et al., 2007
In the citing paper
“The fact that low doses of varenicline (i.e. 0.25 mg/kg in C57BL/6J mice and 0.178 mg/kg in CD-1 mice) have significant effects in both experiments is consistent with varenicline’s high in vitro binding affinity (Ki = 0.15 nM) and inactivating potency (IC50 = 6 nM) at α4β2 nicotinic acetylcholine receptors, as well as with its potent activity in in vivo models, such as increasing mesolimbic”
From Varenicline has antidepressant-like activity in the forced swim test and augments sertraline's effect (2009) · cites this paper as Rollema et al., 2007
In the citing paper
“Varenicline has at least 100-fold higher affinity for α4β2 than for other subtypes, is a 45% agonist as compared with nicotine and can potently desensitize α4β2 nicotinic acetylcholine receptors with an IC50 value of 6 nM for inhibiting nicotine-evoked currents (Rollema et al., 2007).”
From Varenicline has antidepressant-like activity in the forced swim test and augments sertraline's effect (2009) · cites this paper as Rollema et al., 2007
In the citing paper
“Varenicline has at least 100-fold higher affinity for α4β2 than for other subtypes, is a 45% agonist as compared with nicotine and can potently desensitize α4β2 nicotinic acetylcholine receptors with an IC50 value of 6 nM for inhibiting nicotine-evoked currents (Rollema et al., 2007).”
From Varenicline has antidepressant-like activity in the forced swim test and augments sertraline's effect (2009) · cites this paper as Rollema et al., 2007
Citations
Cites
Mortality in relation to smoking: 40 years' observations on male British doctors
Doll, R., Peto, R., Wheatley, K., Gray, R., & Sutherland, I. (1994) · BMJ · doi:10.1136/bmj.309.6959.901 · Cited by 5,932
Neural systems of reinforcement for drug addiction: from actions to habits to compulsion
Everitt, B. J., & Robbins, T. W. (2005) · Nature Neuroscience · doi:10.1038/nn1579 · Cited by 3,785
Mortality in relation to smoking: 50 years' observations on male British doctors
Doll, R., Peto, R., Boreham, J., & Sutherland, I. (2004) · BMJ · doi:10.1136/bmj.38142.554479.ae · Cited by 2,920 · cited 1×
“Department of Health and Human Services, 2004; Doll et al., 2004 ).”
BackgroundThe Health Consequences of Smoking: A Report of the Surgeon General
Office on Smoking (2004) · Cited by 2,414
Charbonneau, D. H. (2005) · Europe PMC (PubMed Central) · Cited by 2,041
Picciotto, M. R., Zoli, M., Rimondini, R., Léna, C., Marubio, L. M., Pich, E. M., Fuxe, K., & Changeux, J.-P. (1998) · Nature · doi:10.1038/34413 · Cited by 1,320
Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs.
Pontieri, F. E., Tanda, G., Orzi, F., & Chiara, G. D. (1996) · Nature · doi:10.1038/382255a0 · Cited by 1,073
Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation
Coe, J. W., Brooks, P. R., Vetelino, M. G., Wirtz, M. C., Arnold, E. P., Huang, J., Sands, S. B., Davis, T. I., Lebel, L. A., Fox, C. B., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050069n · Cited by 930
Self-citation
Flagged first, then by citations
2 of the 44 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 301–400 of 554
Carroll, F. I., Yokota, Y., Ma, W., Lee, J. R., Brieaddy, L. E., Burgess, J. P., Navarro, H. A., Damaj, M. I., & Martin, B. R. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.10.027 · Cited by 16
van Rossem, C., Spigt, M., Smit, E. S., Viechtbauer, W., Mijnheer, K., van Schayck, O. C. P., & Kotz, D. (2015) · Contemporary Clinical Trials · doi:10.1016/j.cct.2015.01.017 · Cited by 16
Kikkawa, H., Maruyama, N., Fujimoto, Y., & Hasunuma, T. (2010) · The Journal of Clinical Pharmacology · doi:10.1177/0091270010372388 · Cited by 16
Clemens, K. J., Lay, B. P. P., & Holmes, N. M. (2015) · Addiction Biology · doi:10.1111/adb.12336 · Cited by 16
Barrett, S. T., Geary, T. N., Steiner, A. N., & Bevins, R. A. (2018) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000404 · Cited by 18
Maggio, S. E., Saunders, M. A., Nixon, K., Prendergast, M., Zheng, G., Crooks, P. A., Dwoskin, L. P., Bell, R. L., & Bardo, M. T. (2018) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2018.09.008 · Cited by 16
Hypotheses Regarding Ayahuasca’s Potential Mechanisms of Action in the Treatment of Addiction
Prickett, J. I., & Liester, M. B. (2013) · Springer eBooks · doi:10.1007/978-3-642-40426-9_7 · Cited by 18
Methamphetamine-Like Discriminative-Stimulus Effects of Nicotinic Agonists
Desai, R. I., & Bergman, J. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.211235 · Cited by 15
Froehlich, J. C., Fischer, S. M., Dilley, J. E., Nicholson, E. R., Smith, T. N., Filosa, N. J., & Rademacher, L. C. (2016) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.13157 · Cited by 15
Ussing, C. A., Hansen, C. P., Petersen, J. G., Jensen, A. A., Rohde, L. A. H., Ahring, P. K., Nielsen, E. Ø., Kastrup, J. S., Gajhede, M., Frølund, B., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm301409f · Cited by 15
Hoestgaard-Jensen, K., Hoestgaard-Jensen, K., & Jensen, A. A. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.509356 · Cited by 15
Sagara, H., Kitamura, Y., Yae, T., Shibata, K., Suemaru, K., Sendo, T., Araki, H., & Gomita, Y. (2008) · Journal of Pharmacological Sciences · doi:10.1254/jphs.08168fp · Cited by 15
Translational Research on Nicotine Dependence
Falcone, M., Lee, B., Lerman, C. E., & Blendy, J. A. (2015) · Current topics in behavioral neurosciences · doi:10.1007/7854_2015_5005 · Cited by 15
Ravva, P., Gastonguay, M. R., Faessel, H. M., Lee, T. C., & NIAURA, R. S. (2014) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntu154 · Cited by 16
Human nicotinic receptors in chromaffin cells: characterization and pharmacology
Albillos, A., & McIntosh, J. M. (2017) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-017-2073-0 · Cited by 16
Tapia, M. A., Jin, X., Tucker, B. R., Thomas, L. N., Walker, N. B., Kim, V. J., Albertson, S. E., Damuka, N., Krizan, I. M., Edassery, S. L., et al. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109066 · Cited by 18
Goutier, W., Kloeze, M. B., & McCreary, A. C. (2013) · Addiction Biology · doi:10.1111/adb.12108 · Cited by 15
LaGamma, E. F., Kirtok, N., Chan, O. T. M., & Nankova, B. B. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00237.2014 · Cited by 15
Kim, M. N., Jutkiewicz, E. M., Zhang, M., & Gnegy, M. E. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.10.003 · Cited by 15
Hone, A. J., McIntosh, J. M., Rueda‐Ruzafa, L., Passas, J., Guerín, C. D. C., Blázquez, J., Enguita, C. G., & Albillos, A. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13883 · Cited by 15
Patel, R. N., Clare, R. H., Ledsgaard, L., Nys, M., Kool, J., Laustsen, A. H., Ulens, C., & Casewell, N. R. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115758 · Cited by 14
Lu, W., Chappell, K. J., Walters, J. A., Jacobson, G. A., Patel, R. P., Schüz, N., & Ferguson, S. G. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4604-y · Cited by 14
Chandler, C. M., Maggio, S. E., Peng, H., Nixon, K., & Bardo, M. T. (2020) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.107988 · Cited by 14
Burstein, A. H., Clark, D. J., O’Gorman, M. T., Willavize, S. A., Brayman, T. G., Grover, G. S., Walsky, R. L., Obach, R. S., & Faessel, H. M. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270007307574 · Cited by 14
Varenicline: progress in smoking cessation treatment
Glover, E. D., & Rath, J. M. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.11.1757 · Cited by 14
The psychobiology of nicotine dependence
Balfour, D. J. K. (2008) · European Respiratory Review · doi:10.1183/09059180.00011001 · Cited by 14
Esaki, H., Deyama, S., Izumi, S., Katsura, A., Nishikawa, K., Nishitani, N., & Kaneda, K. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109672 · Cited by 13
Novel liquid chromatographic methods for the determination of varenicline tartrate
El-Bagary, R. I., Abo-Talib, N. F., & Mohamed, M. A. E.-W. (2015) · Talanta · doi:10.1016/j.talanta.2015.07.077 · Cited by 13
Liu, Y., Richardson, J. R., Tran, T. P., Al‐Muhtasib, N., Xie, T., Yenugonda, V. M., Sexton, H. G., Rezvani, A. H., Levin, E. D., Sahibzada, N., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4000374 · Cited by 13
Macnamara, C. L., Holmes, N. M., Westbrook, R. F., & Clemens, K. J. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.02.023 · Cited by 13
Touchette, J. C., Maertens, J. J., Mason, M. M., O’Rourke, K. Y., & Lee, A. M. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.01.019 · Cited by 13
DiPalma, D. T., Rezvani, A. H., Willette, B. K. A., Wells, C., Slade, S. K., Hall, B. J., & Levin, E. D. (2018) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2018.11.002 · Cited by 13
Wu, J., Cippitelli, A., Zhang, Y., Debevec, G., Schoch, J., Ozawa, A., Yu, Y., Liu, H., Chen, W., Houghten, R. A., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01250 · Cited by 13
Froehlich, J. C., Nicholson, E. R., Dilley, J. E., Filosa, N. J., Rademacher, L. C., & Smith, T. N. (2017) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.13432 · Cited by 12
Huang, Y., Ma, Z., Zheng, C. J., Xiao-kuang, K., Taylor, D. H., Gao, M., Lukas, R. J., & Wu, J. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00709-1 · Cited by 12
Maggio, S. E., Saunders, M. A., Baxter, T. A., Nixon, K., Prendergast, M., Zheng, G., Crooks, P. A., Dwoskin, L. P., Slack, R. D., Newman, A. H., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4853-4 · Cited by 12
Fletcher, P. J., Li, Z., Silenieks, L. B., MacMillan, C., DeLannoy, I., & Higgins, G. A. (2018) · Addiction Biology · doi:10.1111/adb.12602 · Cited by 12
Preclinical and clinical research on the discriminative stimulus effects of nicotine
Shoaib, M. C., & Perkins, K. A. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108063 · Cited by 12
Henderson, B. J., González-Cestari, T. F., Yi, B., Pavlovicz, R. E., Boyd, R. T., Li, C., Bergmeier, S. C., & McKay, D. B. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn300035f · Cited by 12
Wilcox, C. E., Claus, E. D., Calhoun, V. D., Rachakonda, S., Littlewood, R. A., Mickey, J., Arenella, P. B., Goodreau, N., & Hutchison, K. E. (2017) · Addiction Biology · doi:10.1111/adb.12498 · Cited by 12
Discriminative Stimulus Properties of S(−)-Nicotine: “A Drug for All Seasons”
Rosecrans, J. A., & Young, R. (2017) · Current topics in behavioral neurosciences · doi:10.1007/7854_2017_3 · Cited by 12
Garcia‐Rivas, V., Fiancette, J.-F., Cannella, N., Carbo‐Gas, M., Renault, P., Tostain, J., & Deroche‐Gamonet, V. (2019) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2019.00159 · Cited by 12
Jackson, A. E., Silk, S., Buhidma, Y., & Shoaib, M. C. (2016) · Addiction Biology · doi:10.1111/adb.12423 · Cited by 12
Selley, D. E., Banks, M. L., Diester, C. M., Jali, A. M., Legakis, L. P., Santos, E. J., & Negus, S. S. (2020) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.120.000349 · Cited by 11
Effect of Extending the Duration of Prequit Treatment With Varenicline on Smoking Abstinence
Hawk, L. W., Tiffany, S. T., Colder, C. R., Ashare, R. L., Wray, J. M., Tyndale, R. F., Brandon, T. H., & Mahoney, M. C. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.41731 · Cited by 11
Chellian, R., Behnood‐Rod, A., & Bruijnzeel, A. W. (2022) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntac280 · Cited by 11
Gao, R., Schneider, A. M., Mulloy, S., & Lee, A. M. (2023) · European Journal of Neuroscience · doi:10.1111/ejn.16109 · Cited by 12
Translational research in addiction: Toward a framework for the development of novel therapeutics
Paterson, N. E. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.12.017 · Cited by 12
Brees, D., Elwell, M. R., Tingley, F. D., Sands, S. B., Jakowski, A. B., Shen, A. C., Cai, J., & Finkelstein, M. B. (2008) · Toxicologic Pathology · doi:10.1177/0192623308317424 · Cited by 11
Self-citationMcGregor, A. L., D’Souza, G. X., Kim, D., & Tingle, M. D. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.12.021 · Cited by 11
Quintanilla, M. E., Morales, P., Ezquer, F. E., Ezquer, M., Herrera‐Marschitz, M., & Israel, Y. (2021) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2020.617418 · Cited by 11
Efficacy of Varenicline in Patients With Severe Alcohol Dependence
Pfeifer, P., & Fehr, C. (2019) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001056 · Cited by 11
More than Smoke and Patches: The Quest for Pharmacotherapies to Treat Tobacco Use Disorder
Moerke, M. J., McMahon, L. R., & Wilkerson, J. L. (2020) · Pharmacological Reviews · doi:10.1124/pr.119.018028 · Cited by 11
A novel series of [3.2.1] azabicyclic biaryl ethers as α3β4 and α6/4β4 nicotinic receptor agonists
Lowe, J. A., III, DeNinno, S. L., Coe, J. W., Zhang, L., Mente, S., Hurst, R. S., Mather, R. J., Ward, K. M., Shrikhande, A., Rollema, H., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.06.142 · Cited by 11
Self-citationLawson, S. C., Gass, J. C., Cooper, R. K., Tonkin, S., Colder, C. R., Mahoney, M. C., Tiffany, S. T., & Hawk, L. W. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05713-7 · Cited by 10
5-HT2A and 5-HT2C receptors as potential targets for the treatment of nicotine use and dependence
Higgins, G. A., & Sellers, E. M. (2021) · Progress in brain research · doi:10.1016/bs.pbr.2021.01.007 · Cited by 10
Attenuating nicotine’s effects with high affinity human anti-nicotine monoclonal antibodies
Raleigh, M. D., Beltraminelli, N., Fallot, S., LeSage, M. G., Saykao, A. T., Pentel, P. R., Fuller, S., Thisted, T., Biesova, Z., Horrigan, S. K., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0254247 · Cited by 10
Antidepressants enter cells, organelles, and membranes
Blumenfeld, Z., Bera, K., Ċastrén, E., & Lester, H. A. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01725-x · Cited by 10
Current Treatment Options in Smoking Cessation
Crain, D., & Bhat, A. (2010) · Hospital Practice · doi:10.3810/hp.2010.02.279 · Cited by 11
Monárrez‐Espino, J., Galanti, M. R., Hansson, J., Janszky, I., Söderberg, K. C., & Möller, J. (2017) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntx131 · Cited by 10
Kwak, S. S., Lee, E. S., Yoon, H. Y., Kim, C. H., Goo, Y. T., Kang, M. J., Lee, S. K., Lee, B. S., Jeon, H. R., Oh, C. H., et al. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s178456 · Cited by 10
Levin, E. D., Rezvani, A. H., Wells, C., Slade, S. K., Yenugonda, V. M., Liu, Y. U., Brown, M. L., Xiao, Y., & Kellar, K. J. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.12.010 · Cited by 10
The influence of acute varenicline administration on smoking and eating behavior in humans
Stoops, W. W., Vansickel, A. R., Glaser, P. E. A., & Rush, C. R. (2008) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2008.07.001 · Cited by 10
Varenicline‐induced grand mal seizure
Serafini, A., Crespel, A., Velizara, R., & Gélisse, P. (2010) · Epileptic Disorders · doi:10.1684/epd.2010.0339 · Cited by 10
The smoking cessation drug varenicline improves deficient P20–N40 inhibition in DBA/2 mice
Wildeboer, K. M., & Stevens, K. E. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.07.001 · Cited by 9
Specificity of Varenicline in Blocking Mesolimbic Circuit Activation to Natural and Drug Rewards
Goldstein, N., Carty, J. R. E., & Betley, J. N. (2021) · Neuroscience · doi:10.1016/j.neuroscience.2021.12.016 · Cited by 10
Adolescent alcohol and nicotine exposure alters the adult response to alcohol use
Hauser, S. R., Waeiss, R. A., Deehan, G. A., Engleman, E. A., Bell, R. L., & Rodd, Z. A. (2023) · Advances in Drug and Alcohol Research · doi:10.3389/adar.2023.11880 · Cited by 9
Grebenstein, P. E., Harp, J. L., & Rowland, N. E. (2013) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.07.012 · Cited by 9
Moerke, M. J., Zhu, A. Z. X., Tyndale, R. F., Javors, M. A., & McMahon, L. R. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.12.003 · Cited by 9
Withey, S. L., Doyle, M. R., Bergman, J., & Desai, R. I. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.248070 · Cited by 9
Ketcherside, A., Jagannathan, K., Dolui, S., Hager, N., Spilka, N. H., Nutor, C., Rao, H., Franklin, T. R., & Wetherill, R. R. (2020) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2020.18.2.289 · Cited by 10
Differential regulation of alcohol taking and seeking by antagonism at α4β2 and α3β4 nAChRs
Cippitelli, A., Brunori, G., Schoch, J., Armishaw, C. J., Wu, J., Zaveri, N. T., Giulianotti, M. A., Welmaker, G. S., & Toll, L. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4883-y · Cited by 9
Ibrahim, F. A., Aboshabana, R., & Elmansi, H. (2022) · Royal Society Open Science · doi:10.1098/rsos.220628 · Cited by 8
Olsson, Y., Lidö, H. H., Ademar, K., Cadeddu, D., Ericson, M., & Söderpalm, B. (2023) · Journal of Neural Transmission · doi:10.1007/s00702-023-02701-x · Cited by 8
Jensen, A. B., Hoestgaard-Jensen, K., & Jensen, A. A. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.06.005 · Cited by 8
Grover disease may result from the impairment of keratinocytic cholinergic receptors
Paslin, D. A. (2012) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2009.08.015 · Cited by 8
Connery, H. S., & Kleber, H. D. (2007) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.5.2.foc163 · Cited by 8
Koga, M., Kanaoka, Y., Sugiyama, K., Ohishi, K., Ejima, Y., Hisanaga, M., Kataoka, Y., & Yamauchi, A. (2017) · Toxicology · doi:10.1016/j.tox.2017.08.006 · Cited by 8
Galiatsatos, P., Garfield, J. L., Melzer, A. C., Leone, F. T., Farber, H. J., Ruminjo, J. K., & Thomson, C. C. (2020) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202008-971cme · Cited by 8
Emerging drugs for the treatment of tobacco dependence
Ebbert, J. O. (2009) · Expert Opinion on Emerging Drugs · doi:10.1517/14728210802623874 · Cited by 8
de Moura, F. B., & McMahon, L. R. (2016) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000233 · Cited by 8
Sofuoglu, M., Herman, A. I., Robinson, C. D., & Waters, A. J. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-418679-8.00012-5 · Cited by 8
TC299423, a Novel Agonist for Nicotinic Acetylcholine Receptors
Wall, T. R., Henderson, B. J., Voren, G., Wageman, C. R., Deshpande, P., Cohen, B. N., Grady, S. R., Marks, M. J., Yohannes, D., Kenny, P. J., et al. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00641 · Cited by 8
Pintarelli, G., Galvan, A., Pozzi, P., Noci, S., Pasetti, G., Sala, F., Pastorino, U., Boffi, R., & Colombo, F. (2017) · Scientific Reports · doi:10.1038/s41598-017-16946-6 · Cited by 8
Smith, R. C., Zhubi, A., Maloku, E., Sershen, H. W., Lajtha, Á., Davis, J. M., Costa, E., & Guidotti, A. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.02.1064 · Cited by 8
Froehlich, J. C., Fischer, S. M., Nicholson, E. R., Dilley, J. E., Filosa, N. J., Smith, T. N., & Rademacher, L. C. (2017) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.13326 · Cited by 7
Elucidating the reinforcing effects of nicotine: a tribute to Nadia Chaudhri
Sved, A. F., Caggiula, A. R., & Donny, E. C. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06266-7 · Cited by 7
Cortical α4β2-nicotinic acetylcholine receptors and cognitive decline in Parkinson's disease
Mills, K. A., Kuwabara, H., Du, Y., Gómez, G., Motley, C., Skorobogatova, Y., Spiro, E., Coughlin, J. M., Lesniak, W. G., Brandt, J., et al. (2025) · Journal of Parkinson s Disease · doi:10.1177/1877718x241313373 · Cited by 7
Translational Approaches to Medication Development
Bartlett, S. E., & Heilig, M. A. (2011) · Current topics in behavioral neurosciences · doi:10.1007/978-3-642-28720-6_132 · Cited by 7
Johnstone, S., Sorkhou, M., Rabin, R. A., & George, T. P. (2022) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2022.109412 · Cited by 8
Nijm, L. M., Zhu, D., Hemphill, M., Blemker, G., Hendrix, L. H., Kabat, A. G., & Gibson, A. (2022) · Ophthalmology and Therapy · doi:10.1007/s40123-022-00607-7 · Cited by 7
The potential of neuronal nicotinic acetylcholine receptor agonists for treating CNS conditions
Decker, M. W., Gopalakrishnan, M., & Meyer, M. D. (2008) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.3.9.1027 · Cited by 7
Sun, H., Liu, Y., Li, P., Bao, Y., Sheng, L.-X., Zhang, R., Cao, Y., Di, X.-L., Yang, F., Wang, F., et al. (2012) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.01.006 · Cited by 7
A manic episode in a 64-year-old man: an adverse effect of varenicline
Ahmed, A. I. A. (2011) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2010.11.005 · Cited by 7
Behavioral Interventions in Tobacco Dependence
Leone, F. T., & Evers‐Casey, S. (2009) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2009.04.002 · Cited by 7
Kazan, T., Robison, C. L., Cova, N., Madore, V., & Charntikov, S. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112558 · Cited by 7
Bolchi, C., Bavo, F., Fumagalli, L., Gotti, C., Fasoli, F., Moretti, M., & Pallavicini, M. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.10.078 · Cited by 7
Newcombe, D. A. L. (2015) · Journal of Addiction Research & Therapy · doi:10.4172/2155-6105.1000222 · Cited by 7
Pataka, A., Kotoulas, S., Karkala, A., Tzinas, A., Kalamaras, G., Kasnaki, N., Sourla, E., & Stefanidou, E. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12247570 · Cited by 7
Lambert, C. S., Philpot, R. M., Engberg, M. E., Johns, B., & Wecker, L. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.05.056 · Cited by 6
Metadata
- Authors
- Rollema, H., Chambers, L. K., Coe, J. W., Glowa, J., Hurst, R. S., Lebel, L. A., Lu, Y., Mansbach, R. S., Mather, R. J., Rovetti, C. C., Sands, S. B., Schaeffer, E., Schulz, D. W., Tingley, F. D., & Williams, K. E.
- Affiliations
- Pfizer (United States) (US)
- Corresponding author
- Rollema, H.
- Venue
- Neuropharmacology
- Publisher
- Elsevier BV
- Published
- 2007-03
- Volume
- 52
- Issue
- 3
- Pages
- 985-994
- ISSN
- 0028-3908 (ISSN-L)
- OpenAlex
- W2101520329
- Cited by
- 533
- References
- 44
- Citations by year
- 2026: 9 · 2025: 6 · 2024: 9 · 2023: 13 · 2022: 16 · 2021: 19 · 2020: 27 · 2019: 25 · 2018: 27 · 2017: 20 · 2016: 27 · 2015: 37 · 2014: 34 · 2013: 34 · 2012: 41
- FWCI
- 13.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neuropharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- varenicline, α4β2 nicotinic acetylcholine receptor, partial agonism, smoking cessation, nicotine self-administration, dopamine release, nucleus accumbens, receptor binding affinity
- MeSH terms
- Varenicline, Animals, Behavior, Animal, Benzazepines, Brain, Cell Line, Transformed, Dopamine, Dose-Response Relationship, Drug, Drug Administration Schedule, Humans, Male, Membrane Potentials, Nicotine, Protein Binding, Quinoxalines, Self Administration, Transfection, Smoking Cessation, Rats, Sprague-Dawley, Patch-Clamp Techniques, Nicotinic Agonists, Rats, Long-Evans, Rats, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
